More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$11.41B
EPS
1.1
P/E ratio
62.4
Price to sales
9.35
Dividend yield
0.441%
Beta
1.288875
Previous close
$72.79
Today's open
$72.80
Day's range
$72.59 - $72.86
52 week range
$43.20 - $72.88
show more
CEO
Kim Kelderman
Employees
3000
Headquarters
Minneapolis, MN
Exchange
Nasdaq Global Select
Shares outstanding
157090727
Issue type
Common Stock
Healthcare
Biotechnology & Life Sciences
TECH Q1 Earnings & Revenues Beat, Merck KGaA Merger Deal Advances
Bio-Techne's Q1 fiscal 2027 earnings and revenues beat estimates, driven by Protein Sciences growth, as its merger with Merck KGaA moves closer to completion.
Zacks Investment Research • Nov 9, 2026

BIO-TECHNE DECLARES DIVIDEND
MINNEAPOLIS, Nov. 3, 2026 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) announced that its Board of Directors has decided to pay a dividend of $0.08 per share for the quarter ended September 30, 2026. The quarterly dividend will be payable November 23, 2026, to all common shareholders of record at the close of business on November 13, 2026, provided Bio-Techne's previously announced transaction with Merck KGaA, Darmstadt, Germany has not closed on or before the close of business on November 13, 2026.
PRNewsWire • Nov 4, 2026

Bio-Techne's Q1 Earnings on Deck: What's in Store for the Stock?
TECH's Q1 earnings are on deck, with revenues and EPS growth expected as investors weigh segment performance and the pending $11.3 billion acquisition.
Zacks Investment Research • Nov 2, 2026

Conestoga SMid Cap Composite Q3 2026 Portfolio Activity
We initiated a position in Allegro because vehicle electrification, driver-assistance systems and other electronic features are increasing chip content per vehicle. We initiated a position in Sterling Infrastructure because its scale and experience help it win complex, mission-critical projects. We sold Workiva stock to reduce the portfolio's exposure to software, which has been a battleground for investors as it's deemed a potential area of disruption for AI.
Seeking Alpha • Oct 28, 2026

Bio-Techne Expands Global GMP Manufacturing Network with New Bristol Facility to Advance Scalable Cell Therapy Development
Investment strengthens Bio-Techne's global GMP manufacturing infrastructure for cell therapy applications New Bristol facility expands GMP small molecule production capacity and complements recent investments in North America Combined capabilities across Bristol, St. Paul and Minneapolis support customers from discovery through commercial manufacturing MINNEAPOLIS, Oct. 8, 2026 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH), a global provider of life science tools, reagents and diagnostic products, today announced the opening of a new manufacturing facility for Good Manufacturing Practice (GMP) grade small molecules in Bristol, United Kingdom, further expanding the company's global capabilities to support the rapidly growing cell therapy market. The investment reflects Bio-Techne's commitment to helping therapy developers address one of the industry's most pressing challenges: establishing scalable, reproducible manufacturing processes that can support programs from early development through commercialization.
PRNewsWire • Oct 8, 2026

INCY or TECH: Which Is the Better Value Stock Right Now?
Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Incyte (INCY) and Techne (TECH). But which of these two stocks is more attractive to value investors?
Zacks Investment Research • Sep 30, 2026

Bio-Techne Shareholders Approve Acquisition by Merck KGaA, Darmstadt, Germany
MINNEAPOLIS, Sept. 23, 2026 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) ("Bio-Techne"), a global provider of life science tools, reagents and diagnostic products, announced that Bio-Techne shareholders voted to approve and adopt the definitive agreement under which Merck KGaA, Darmstadt, Germany proposes to acquire Bio-Techne (the "Merger Agreement") at a Special Meeting of Shareholders held today.
PRNewsWire • Sep 23, 2026

Bio-Techne Opens New Customer Experience Center in Düsseldorf to Accelerate Scientific Discovery and Customer Collaboration
New flagship facility provides hands-on access to Bio-Techne technologies, workflows and scientific expertise Regional hub will support researchers and organizations across the DACH and broader EMEA regions Center strengthens collaboration, training and innovation within Europe's life sciences community MINNEAPOLIS and DÜSSELDORF, Germany, Sept. 22, 2026 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH), a global provider of life science tools, reagents and diagnostic products, today announced the opening of its new Customer Experience Center in Düsseldorf, Germany, a flagship facility designed to bring European customers closer to Bio-Techne's latest innovations and scientific expertise.
PRNewsWire • Sep 22, 2026

Why Is Techne (TECH) Down 0.1% Since Last Earnings Report?
Techne (TECH) reported earnings 30 days ago. What's next for the stock?
Zacks Investment Research • Sep 11, 2026

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Centerspace (NYSE – CSR), Fulcrum Therapeutics, Inc. (Nasdaq – FULC), Weave Communications, Inc. (NYSE – WEAV), Bio-Techne Corporation (Nasdaq – TECH)
BALA CYNWYD, Pa., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you.
GlobeNewsWire • Sep 9, 2026

¹ Disclosures

Open an M1 investment account to buy and sell Bio-Techne Corp commission-free¹. Build wealth for the long term using automated trading and transfers.